| 李鸿涛,罗 琳,马斌林.分子靶向药物在乳腺癌中研究进展[J].肿瘤学杂志,2017,23(3):175-179. |
| 分子靶向药物在乳腺癌中研究进展 |
| Research Progress of Molecular Targeted Drugs in Treatment of Breast Cancer |
| 投稿时间：2016-10-21 |
| DOI：10.11735/j.issn.1671-170X.2017.03.B003 |
|
 |
| 中文关键词: 靶向药物 乳腺肿瘤 研究进展 |
| 英文关键词:targeted drugs breast cancer progress |
| 基金项目:新疆维吾尔自治区自然科学基金（2014211C116） |
|
| 摘要点击次数: 2170 |
| 全文下载次数: 824 |
| 中文摘要: |
| 摘 要：分子靶向药物治疗是乳腺癌重要的治疗手段。研究表明，在Her-2阳性乳腺癌患者中，使用靶向药物曲妥珠单抗能明显改善预后，无病生存期可提高20%~30%。手术、放化疗与靶向治疗的联合应用，具有治疗靶点明确、临床获益确切、副反应少等优点，寻找多靶点共同抑制乳腺癌侵袭与转移是未来研究的重要方向。 |
| 英文摘要: |
| Abstract：Molecular targeted drug therapy becomes an important therapeutic modality for breast cancer. Studies have shown that targeted drug can significantly improve the prognosis of cancer patients; for example trastuzumab(Herceptin) can increase disease-free survival(DFS) by 20%~30% in Her-2 positive breast cancer patients. Combined with surgery，radiotherapy and chemotherapy，targeted therapy will bring more clinical benefits with less side effect. For future research focus，it is important to find multiple targets to inhibit invasion and metastasis of breast cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |